GlassScriptPhysician profile
Stephanie P Maggard
NPI 1154719763
$783.81
in general payments reported to CMS, 2019-2025
18 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $144 · 2023: $61.36 · 2024: $186 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $114.37 | 2024-2025 | Fanapt |
| Abbvie INC. | $111.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $108.79 | 2023-2025 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.08 | 2021-2022 | |
| Amgen INC. | $65.07 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.02 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $35.67 | 2022-2024 | |
| Novo Nordisk INC | $28.65 | 2022-2023 | |
| Indivior INC. | $26.95 | 2024 | Sublocade |
| Glaxosmithkline, LLC. | $23.19 | 2021 | |
| Medtronic, INC. | $20.73 | 2024 | Minimed 780g |
| Shield Therapeutics INC | $18.16 | 2023 | Accrufer |
| Soleno Therapeutics, INC. | $15.39 | 2025 | Vykat Xr |
| Abbott Laboratories | $15.17 | 2022 | |
| Sun Pharmaceutical Industries INC. | $14.93 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.34 | 2023 | Breztri |
| Mylan Specialty L.P. | $12.55 | 2021 | |
| Merck Sharp & Dohme LLC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Maggard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.